FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in TreatmentPublished: February 20, 2025On January 27,…
FDA Approves Datopotamab Deruxtecan / Datroway from Eli Lilly in Treatment for Unresectable or Metastatic HR-Positive, HER2-Negative Breast Cancer Breast 2 Mins Read Date: February 8, 2025The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a new…
